Bethany Kinsey, NP
Family · San Francisco, CANPI 1437546819
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $26,247 of the $33,309 with a category attached, or 78.8%. Sanofi-aventis U.S. LLC accounts for 93.2% of it on its own, with 21 other manufacturers making up the rest. Among family clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 145 payments — averaging $229.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi-aventis U.S. LLC$31K
- Mannkind Corporation$643
- Tandem Diabetes Care, Inc.$333
- Corcept Therapeutics$199
- Novo Nordisk$176
- Amgen$139
- plus $764 from 16 others
What the payments were for
- Consulting fees$2,6888%
- Speaking & faculty fees$26,24779%
- Travel & lodging$9553%
- Food & beverage$3,31810%
- Education$410%
- Gifts$590%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sanofi-aventis U.S. LLC | 54 | $31,055 |
| Mannkind Corporation | 19 | $643 |
| Tandem Diabetes Care, Inc. | 9 | $333 |
| Corcept Therapeutics | 8 | $199 |
| Novo Nordisk | 10 | $176 |
| Amgen(2 entities) | 7 | $139 |
| Abbott | 8 | $131 |
| Insulet Corporation | 6 | $103 |
| Kyowa Kirin, Inc. | 1 | $84 |
| Dexcom, Inc. | 3 | $68 |
| Medtronic | 3 | $61 |
| Cequr Corporation | 2 | $58 |
| Xeris Pharmaceuticals, Inc. | 3 | $51 |
| Ascensia Diabetes Care US Inc. | 2 | $40 |
| Bayer | 2 | $35 |
| Amneal Pharmaceuticals LLC | 2 | $32 |
| Pfizer | 1 | $20 |
| AstraZeneca | 1 | $18 |
| AbbVie | 1 | $17 |
| Lilly USA, LLC | 1 | $17 |
| Recordati_rare_diseases_inc. | 1 | $15 |
| IBSA Pharma Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TZIELD$25,241
- t:slim X2 Insulin Pump with Control-IQ$225
How this compares
$33,309 in reported general payments places this provider in the 95th percentile of 10,634 family providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 189 | $276,655 |
| MounjaroTirzepatide | 154 | $196,832 |
| JardianceEmpagliflozin | 96 | $105,749 |
| TrulicityDulaglutide | 43 | $68,157 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 46 | $65,282 |
| Xultophy 100-3.6Insulin Degludec/Liraglutide | 13 | $31,689 |
| Tresiba Flextouch U-100Insulin Degludec | 55 | $30,514 |
| RybelsusSemaglutide | 14 | $26,371 |
| AfrezzaInsulin Regular, Human | 11 | $18,645 |
| Humalog Kwikpen U-200Insulin Lispro | 11 | $17,259 |
| Tresiba Flextouch U-200Insulin Degludec | 20 | $15,795 |
| FarxigaDapagliflozin Propanediol | 12 | $13,802 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 27 | $13,636 |
| TradjentaLinagliptin | 14 | $13,229 |
| Novolog FlexpenInsulin Aspart | 36 | $9,837 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Xultophy 100-3.6, Rybelsus, Novolog | $176 | $338,730227 claims |
| Lilly USA, LLCMounjaro, Trulicity, Humalog, Insulin Lispro | $17 | $268,960222 claims |
| Mannkind CorporationAfrezza | $643 | $18,64511 claims |
| AstraZenecaFarxiga | $18 | $13,80212 claims |
| AbbVieSynthroid | $17 | $4,42056 claims |
| IBSA Pharma Inc.Tirosint | $14 | $2,00512 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $32 | $1,987182 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 10,634 family providers in California.
Other family in San Francisco
- Gabriel SchwartzSan Francisco$166K
- Annika EhrlichSan Francisco$128K
- Monica VolzSan Francisco$96K
- Lori RobertsonChino Hills$475K
- Annette ShonLos Angeles$406K
- Lisa HigginsHanford$311K
- Jennifer TougasBakersfield$302K
- Kim SchaferSacramento$288K
- Dawn MeyerSan Diego$270K
- Jennifer KangCerritos$255K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.